Hypertrophic cardiomyopathy: A modern view on the diagnosis and management of patients (review)
Journal: Siberian Journal of Clinical and Experimental Medicine
Year: 2022

Hypertrophic cardiomyopathy (HCM) is a genetically determined disease with a high prevalence and manifestation at the age of 30–40 years. Currently available most effective treatments are extended myectomy and Morrow septal myectomy. However, the frequent occurrence of postoperative complications and restrictions to the use of these methods in certain groups of patients provides rationale for the improvement of the existing treatment methods and search for new pharmacological approaches. One of